CrushSCI.com
110.1平均天数
83中位天数
33最短天数
211最长天数
1852025发文量

Paper Review Records

全部论文审稿周期

15 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

64 天

Detection of Actionable Genomic Alterations beyond EGFR, ALK and ROS1 in Non-Small Cell Lung Carcinoma: A Real-World Evaluation of a Pathology-Led Staggered Reflex Predictive Biomarker Testing Strategy in a Resource-Limited Setting

作者
Aruna Nambirajan; Kaustar Yadav; Saumya Sahu; Snehvarsha Bhagat; Prajna Gopalakrishna; Shraddanjali Satapathy; Warisa Khatoon; Suyash Devgan; Amita Singh; Aparna Sharma; Anant Mohan; Prabhat Singh Malik; Chitra Sarkar; Deepali Jain展开收起
作者单位
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India; Department of Medical Oncology, NCI Jhajjar, All India Institute of Medical Sciences, New Delhi, India; Department of Pulmonary and Sleep Medicine, All India Institute of Medical Sciences, New Delhi, India; Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India; Thoracic Pathology Center of Excellence, University of Pittsburgh Medical Center, Pittsburgh, PA, USA展开收起
PDF源文件 DOI 网页
75 天

Real-World Outcomes and Early Progressive Disease Analysis of Nivolumab and Ipilimumab Combination Therapy in Metastatic NSCLC: LIGHT-NING Study 2.5-Year Update

作者
Hisao Imai; Teppei Yamaguchi; Koichi Azuma; Takashi Kijima; Yukihiro Toi; Kazuma Kishi; Kohei Fujita; Haruhiro Saito; Yoshimasa Shiraishi; Junko Tanizaki; Yuta Takashima; Yuichi Tambo; Satoshi Watanabe; Osamu Hataji; Tatsuro Fukuhara; Tomoyuki Ohsugi; Yu Tobishima; Hidehito Horinouchi展开收起
作者单位
Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan; Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Division of Respirology, Neurology and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan; Department of Respiratory Medicine and Hematology, Hyogo Medical University, School of Medicine, Nishinomiya, Hyogo, Japan; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Miyagi, Japan; Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo, Japan; Division of Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Fushimi-ku, Kyoto, Japan; Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Medical Oncology, Kindai University Faculty of Medicine, Sakai, Osaka, Japan; Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan; Department of Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Chuo-ku, Niigata, Japan; Respiratory Center, Saiseikai Matsusaka Municipal Hospital, Matsusaka, Mie, Japan; Department of Respiratory Medicine, Miyagi Cancer Center, Natori, Miyagi, Japan; Oncology Medical, Bristol Myers Squibb, Tokyo, Japan; Oncology Medical Affairs, Ono Pharmaceutical Co., Ltd., Osaka, Japan; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan展开收起
PDF源文件 DOI 网页
138 天

Modified CARG Score-Guided First-Line Treatment in Older or Vulnerable Patients With Advanced Non-Small-Cell Lung Cancer: Results of the Randomized, Phase 2 DURATION Trial (AIO-YMO/TRK-0416)

作者
Jonas Kuon; Miriam Blasi; FFarastuk Bozorgmehr; Konrad Kokowski; Martin Faehling; Philipp Schütt; Daniel Christoph Christoph; Martin Kimmich; Eva Lotte Buchmeier; Anke Reinacher-Schick; Matthias Ulmer; Christian Meyer zum Büschenfelde; Nicolas Moosmann; Frank Griesinger; Wolfang Schütte; Ludwig Fischer von Weikersthal; Bernd Schmidt; Wolfgang Gleiber; Heinz Kirchen; Martin Wermke; Paul La Rosé; Gerlinde Schmidtke-Schrezenmeier; Jean-Charles Moulin; Michael Boesche; Christian Grohé; Helga Bernhard; Dominik Modest; Christoph Maintz; Marc Alexander Schneider; Rouven Behnisch; Albrecht Stenzinger; Petros Christopoulos; Michael Thomas展开收起
作者单位
Department of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg TLRC-H, Member of the German Center for Lung Research (DZL), Heidelberg, Germany; Department of Thoracic Oncology, SLK Fachklinik Löwenstein, Löwenstein, Germany; Department for Pneumology and Thoracic oncology, Klinikum Bogenhausen, Bogenhausen, Germany; Department of Cardiology and Pneumology, Hospital Esslingen, Esslingen, Germany; Department Oncological Practice Gütersloh, Gütersloh, Germany; Department of Pneumology and Infectiology, Division of Thoracic Oncology, Thoraxzentrum Evang. Krankenhaus Herne-Eickel, Thoraxzentrum Ruhrgebiet, Herne, Germany; Department of Thoracic Oncology, Robert-Bosch-Hospital Stuttgart, Stuttgart, Germany; Department of Pneumology, Lung Hospital Cologne Merheim, City of Cologne Municipal Hospitals, Cologne, Germany; Lung Clinic Hemer, Department of Pulmonology and Thoracic Oncology, Hemer, Germany; Department of Hematology and Oncology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany; Department of Hematology and Oncolgy, Hospital Ludwigsburg, Ludwigsburg, Germany; Clinic for Hematology, Oncology, Immunology and Palliative Care, St. Vincentius Hospital Karlsruhe, Karlsruhe, Germany; Department of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany; Department of Hematology and Oncology, Pius-Hospital, University Medicine Oldenburg University Department Internal Medicine-Oncology, Oldenburg, Germany; Department Internal Medicine II, Hospital Martha-Maria Halle-Dölau, Halle Saale, Germany; Department of Hematology and Oncology, St. Marien Hospital, Amberg, Germany; Department of Pneumology, DRK-Kliniken Berlin Mitte, Berlin, Germany; Department of Pneumology, Universitätsklinikum Frankfurt, Frankfurt, Germany; Department of Oncology, Hospital Barmherzigen Brüder Trier, Trier, Germany; Department NCT/UCC Early Clinical Trial Unit, Technische Universität Dresden, Dresden, Germany; Department of Oncology, Schwarzwald-Baar Klinikum, Villingen-Schwenningen, Germany; Department of Pneumology, Universitätsklinikum Ulm, Ulm, Germany; Department of Hematology and Oncology, Ortenau Klinikum Lahr, Ortenau, Germany; Department of Pneumology, Universitätsmedizin Greifswald, Greifswald, Germany; Department of Pneumology, Ev. Lungenklinik Berlin, Berlin, Germany; Department of Oncology, Klinikum Darmstadt, Darmstadt, Germany; Department of Oncology Klinikum München Großhadern, München, Germany; Medical Care Centre West Haematology-Oncology, Würselen, Germany; Translational Research Unit, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany; Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany展开收起
PDF源文件 DOI 网页
42 天

Pretreatment FDG-PET Biomarkers Predict Regional and Distant Failure but Not Local Recurrence Following Modern Use of Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer

作者
Dasantha Jayamanne; Joseph Chan; Riche Mohan; Sameer Dave; Sally Ayesa; Geoff Schembri; Venkatesha Venkatesha; Nick Pavlakis; Malinda Itchins; Alex Davis; Ben Harris; Michael Hibbert; Garrick Don; Stephen Clarke展开收起
作者单位
Radiation Oncology, Northern Sydney Local Health District Executive, Royal North Shore Hospital, Sydney, New South Wales, Australia; Sydney University Medical Faculty, Sydney, New South Wales, Australia; Nuclear Medicine, Northern Sydney Local Health District Executive, Royal North Shore Hospital, Sydney, New South Wales, Australia; Research Directorate, Northern Sydney Local Health District Executive, Royal North Shore Hospital, Sydney, New South Wales, Australia; Medical Oncology, Northern Sydney Local Health District Executive, Royal North Shore Hospital, Sydney, New South Wales, Australia; Respiratory Medicine, Northern Sydney Local Health District Executive, Royal North Shore Hospital, Sydney, New South Wales, Australia展开收起
PDF源文件 DOI 网页
77 天

Stage I Lung Adenocarcinoma in Young Patients (Aged ≤ 50 Years): Beyond Female Nonsmokers

作者
Hina Bhat; Hely Ollila; Amina Tidjani; Victoria Cranwell; Vincent Galea; Soo-Ryum Yang; Gaetano Rocco; Matthew J. Bott; David R. Jones; Prasad S. Adusumilli展开收起
作者单位
Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY展开收起
PDF源文件 DOI 网页
73 天

Using Induction Chemoimmunotherapy as a Bridge to Definitive Local Therapy for Non-Metastatic NSCLC: Real-World Outcomes From a Comprehensive Cancer Center

作者
Troy J. Kleber; Sage A. Copling; Andrew D. Kim; César P. Márquez; Wenli Dong; Waree Rinsurongkawong; Vadeerat Rinsurongkawong; J. Jack Lee; Yuliya Kitsel; Xiaoyu Han; Sherif M. Ismail; Hui Xu; Ivan Coronado; Zhongxing Liao; Joe Y. Chang; Aileen Chen; Saumil Gandhi; Matthew S. Ning; Quynh-Nhu Nguyen; Michael S. O’Reilly; David Qian; James W. Welsh; Stephen G. Chun; Tina Cascone; Jianjun J. Zhang; Don L. Gibbons; Mehmet Altan; Ara A. Vaporciyan; David C. Rice; Ravi Rajaram; Reza J. Mehran; Mara B. Antonoff; Kyle G. Mitchell; Annikka Weissferdt; John V. Heymach; Jia Wu; Steven H. Lin; Julianna K. Bronk展开收起
作者单位
Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; McGovern Medical School at UTHealth Houston., Houston, TX; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Imaging Physics, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX; Institute for Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Thoracic Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Thoracic-Head & Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Thoracic and Cardiovascular Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Anatomical Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX展开收起
PDF源文件 DOI 网页

FAQ

Clinical Lung Cancer审稿要多久?

截至2026-11-14,CrushSCI 收录了 Clinical Lung Cancer 的 15 篇完整审稿记录。最快一篇从收稿到录用用了 33 天(Rationale and Study Design of the GUIDANCE trial: A Multicenter Phase II Trial of Maintenance Durvalumab and Olaparib After Standard Fist Line Treatment (Carboplatin/Cisplatin, Etoposide, and Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (AIO-TRK-0124/ass),2026-06-30 收稿,2026-08-02 录用),最慢一篇用了 211 天;平均 110.1 天,中位数 83 天。

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。